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Assessing the variability and predictability
of adipokines (adiponectin, leptin, resistin
and their ratios) in non‑obese and obese
women with anovulatory polycystic ovary
syndrome
Christian Obirikorang1, William K. B. A. Owiredu1, Sandra Adu‑Afram1, Emmanuel Acheampong2,
Evans Adu Asamoah1, Enoch Kwabena Antwi‑Boasiakoh3 and Eddie‑Williams Owiredu1*

Abstract
Objectives: To assess the variability and predictability of adiponectin, leptin, resistin and their ratios in non-obese
and obese women with anovulatory polycystic ovary syndrome (aPCOS).
Results: A total of 52 ovulatory controls (mean age = 31.63 ± 4.88 years, BMI = 25.33 ± 2.68 kg/m2); 54 nonobese (mean age = 32.11 ± 4.25 years, BMI = 25.72 ± 2.95 kg/m2) and 50 obese women with aPCOS (mean
age = 33.64 ± 4.14 years, BMI = 39.19 ± 2.99 kg/m2) were recruited. The aPCOS group had lower adiponectin [13.0
(10.49–16.59) vs 18.42 (15.72–19.92) µg/ml, p < 0.0001], adiponectin: leptin ratio (A:L) [0.60 (0.35–0.88) vs 1.19 (0.92–
1.37), p < 0.0001], and adiponectin: resistin ratio (A:R) [0.30 (0.21–0.43) vs 0.42 (0.32–0.62), p < 0.0001] but a higher lep‑
tin [20.02 (14.54–26.80) vs 16.17 (14.51–18.36) ng/ml, p < 0.0001] and leptin: resistin ratio (L:R) [0.53 (0.37–0.82) vs 0.40
(0.27–0.48), p < 0.0001] compared to the controls. The obese aPCOS group had lower adiponectin [11.04 (5.66–13.25)
vs 14.18 (11.04–18.02), p < 0.0001 and 18.42 (15.72–19.92) µg/ml, p < 0.0001], A:L [0.36 (0.27–0.44) vs 0.78 (0.61–1.16),
p < 0.0001 and 1.19 (0.92–1.37), p < 0.0001], and A:R [0.24 (0.17–0.38) vs 0.40 (0.23–0.58), p < 0.0001 and 0.42 (0.32–
0.62), p < 0.0001] but a higher leptin [26.80 (14.28–32.09) vs 17.95 (14.86–21.26), p < 0.05 and 16.17 (14.51–18.36) ng/
ml, p < 0.0001] and L:R [0.63 (0.46–1.03) vs 0.41 (0.30–0.61), p < 0.0001 and 0.40 (0.27–0.48), p < 0.0001] compared to
the non-obese aPCOS and control group, respectively. A:L showed the best discriminatory power in predicting aPCOS
(AUC = 0.83), followed by adiponectin alone (AUC = 0.79), L:R and leptin alone (both AUC = 0.69). Resistin alone had
the poorest discriminatory power (AUC = 0.48).
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Introduction
Overweight and obesity are pervasive conditions which
are considered global epidemic and threat to public
health [1, 2]. Evidence suggest that obesity is associated with the risk of metabolic diseases such as diabetes,
hypertension, cardiovascular disease, cancers and overall
mortality [3–5]. There have also been reports of associations between obesity and infertility [6, 7], particularly among women due to the risk of anovulation [1, 8].
Anovulation is a common cause of infertility in women;
responsible for 25–50% of female infertility [9, 10], of
which polycystic ovary syndrome (PCOS) accounts over
90% of cases [11].
PCOS is a multisystem, endocrinological, reproductive
and metabolic disorder characterized by oligo- and/or
anovulation, hyperandrogenism, and polycystic ovaries
[12]. Obesity-related adverse alterations in adipose tissue that predispose to metabolic dysregulation has been
implicated in PCOS pathogenesis. These adverse alterations include derangements in bioactive cytokines and
adipokines such as adiponectin, leptin, and resistin [13,
14].
Adiponectin is an adipokine secreted by adipose tissues, with anti-inflammatory, anti-atherogenic, cardioprotective, and insulin-sensitizing properties. Reduced
adiponectin levels have been linked with obesity, T2DM,
and PCOS [15–17]. Nonetheless, the relationship
between altered adiponectin levels and PCOS remains
debatable. While some studies report lower adiponectin levels in PCOS independent of BMI [13, 18], others
report similar adiponectin levels in BMI-matched PCOS
and controls [19, 20]. Leptin is an anorexigenic peptide
hormone secreted by white adipose tissue [21]. Likewise,
whereas some studies report a significant positive association between circulating leptin levels with high body
fat independent of PCOS [22], others report no significant difference in circulating leptin levels between PCOS
and age- and BMI-matched controls [23, 24] as well as
between ovulatory and anovulatory women with PCOS
[25]. Resistin is an adipocyte-derived polypeptide which
have been associated with obesity, insulin resistance (IR)
and cardiovascular risk [26, 27]. Similarly, some studies
report comparable resistin levels between women with
PCOS and controls [17, 27, 28] while others indicate that,
irrespective of PCOS, there are elevated resistin levels in
obese women compared to non-obese [29].
Thus far, reports regarding the alterations in adiponectin, leptin, and resistin in non-obese and obese women
with PCOS remain inconclusive. Additionally, despite
numerous previous studies highlighting the expediency
of the ratios of these adipokines as a biomarker for obesity, IR, diabetes, coronary artery disease, and stroke [30–
33], there is a dearth of information on their expediency

Page 2 of 8

as predictors of PCOS. This study aimed at assessing
the variability and predictability of adiponectin, leptin,
resistin and their ratios in non-obese and obese women
with anovulatory PCOS.

Main text
Materials and methods
Study design/setting

This was a case–control study. Consecutive consenting women clinically diagnosed of aPCOS visiting the
Obstetrics and Gynaecology units of Trust Care, Ruma
and Asbury were included in the study as cases. PCOS
diagnosis was based on the 2003 Rotterdam criteria [12].
All PCOS participants were anovulatory. Fertile (eumenorrheic) women visiting the hospital for routine check-up
were included as controls. Relevant clinical data of each
participant was extracted from the hospital’s archive.
Women with Cushing syndrome, hyperprolactinemia,
androgen-producing tumors, non-classic adrenal hyperplasia, active thyroid disease, and diabetes were excluded.
Study population and Anthropometric measurements

A total of 52 ovulatory, 54 non-obese and 50 obese
women with aPCOS were included in this study. The
weight was measured using a calibrated analogue scale
(Seca, Hamburg, Deutschland). Height was measured
using a stadiometer (Seca, Hamburg, Deutschland).
Body mass index (BMI) was calculated by: BMI = weight/
height2 (kg/m2) [34]. Obesity was defined according to the World Health Organization (WHO) criteria
(BMI ≥ 30 kg/m2) [35]. Waist circumference (WC) and
hip circumference (HC) were measured with a measuring tape; waist-to-height ratio (WHtR) = WC (m)/
height (m), waist-to-hip ratio (WHR) = WC (m)/HC (m),
body adiposity index (BAI) = (100 × HC (m))/(height
(m) × √height (m)) − 18 [36] and visceral adiposity
index
(VAI) = (WC(m))/(36.58 + (1.89 × BMI)) × (TG/
(0.81)) × ((1.52)/HDL-C) were calculated.
Blood sampling, processing and analysis

Five milliliters of venous blood was obtained from each
participant and dispensed into gel separator tubes. The
tubes were centrifuged at 1500×g for 10 min at 4 °C to
obtain the serum which were stored at − 20 °C until analysis. Serum levels of adiponectin, leptin, and resistin were
measured based on solid-phase sandwich Enzyme Linked
Immunosorbent Assay (ELISA) technique (standardized
with an intra- and inter-assay %CVs < 10%) (Green Stone
Swiss Co Limited, China) according to the manufacturer’s instructions.
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Statistical analysis

Statistical analysis was performed using the R Language for Statistical Computing version 3.6.0 [37]. Chi
squared test was used to assess significance of association between the participant characteristics and fertility status. Distribution of adipokines were presented
with density plots. Hierarchical clustering by Spearman’s correlation was used to assess relationship between
adipokines (and their ratios) and obesity indices. Independent t-test and one-way ANOVA with Tukey test or
Mann–Whitney U and Kruskal–Wallis with Dunn’s test
were used to test for significance of difference between
groups where applicable. The receiver operating characteristic (ROC) curve analysis was used to evaluate the
performance of the adipokines (and their ratios) in predicting aPCOS. A p value < 0.05 was considered statistically significant.
Results

A
total
of
52
ovulatory
controls
(mean
age = 31.63 ± 4.88 years, BMI = 25.33 ± 2.68 kg/m2);
104 aPCOS patients comprising 54 non-obese [mean
age = 32.11 ± 4.25 years, BMI = 25.72 ± 2.95 kg/m2]
and 50 obese women [mean age = 33.64 ± 4.14 years,
BMI = 39.19 ± 2.99 kg/m2] were included in this study. A

higher proportion of the study participants had tertiary
education, were employed and did not consume alcohol.
There was no statistically significant association between
fertility status and baseline characteristics (Table 1).
The aPCOS group had a significantly lower adiponectin
[13.0 (10.49–16.59) µg/ml vs 18.42 (15.72–19.92) µg/ml,
p < 0.0001], adiponectin: leptin ratio (A:L) [0.60 (0.35–
0.88) vs 1.19 (0.92–1.37), p < 0.0001], and adiponectin:
resistin ratio (A:R) [0.30 (0.21–0.43) vs 0.42 (0.32–0.62),
p < 0.0001] but higher leptin [20.02 (14.54–26.80) ng/
ml vs 16.17 (14.51–18.36) ng/ml, p < 0.0001] and leptin:
resistin ratio (L:R) [0.53 (0.37–0.82) vs 0.40 (0.27–0.48),
p < 0.0001] compared to the controls (Fig. 1a, b).
The obese aPCOS group had a significantly lower adiponectin [11.04 (5.66–13.25) µg/ml vs 14.18 (11.04–
18.02) µg/ml, p < 0.0001 and 18.42 (15.72–19.92) µg/ml,
p < 0.0001], A:L [0.36 (0.27–0.44) vs 0.78 (0.61–1.16),
p < 0.0001 and 1.19 (0.92–1.37), p < 0.0001], and A:R [0.24
(0.17–0.38) vs 0.40 (0.23–0.58), p < 0.0001 and 0.42 (0.32–
0.62), p < 0.0001] but higher leptin [26.80 (14.28–32.09)
ng/ml vs 17.95 (14.86–21.26) ng/ml, p < 0.05 and 16.17
(14.51–18.36) ng/ml, p < 0.0001] and L:R [0.63 (0.46–
1.03) vs 0.41 (0.30–0.61), p < 0.0001 and 0.40 (0.27–0.48),
p < 0.0001] compared to the non-obese aPCOS and control group, respectively (Fig. 1c, d).

Table 1 Baseline characteristics of the study population
Variable

Ovulatory control
(n = 52)

PCOS (n = 104)

p-value

Non-obese PCOS
(n = 54)

Obese PCOS (n = 50)

p-value

Age (years)

31.63 ± 4.88

32.85 ± 4.25

0.112‡

32.11 ± 4.25

33.64 ± 4.14

0.062†

5 (21.7)

18 (78.3)

12 (52.2)

6 (26.1)

Educational level
None/basic

0.312

Secondary

14 (41.2)

20 (58.8)

12 (35.3)

8 (23.5)

Tertiary

33 (33.3)

66 (66.7)

30 (30.3)

36 (36.4)

9 (47.4)

10 (52.6)

8 (42.1)

2 (10.5)

Occupation
Unemployed

0.197

0.093

Employed

43 (31.4)

94 (68.6)

46 (33.6)

48 (35.0)

  Informal

10 (29.4)

24 (70.6)

10 (29.4)

14 (41.2)

  Formal

33 (32.0)

70 (68.0)

36 (35.0)

34 (33.0)

22 (32.8)

28 (41.8)

Frequency of exercise
Rarely

0.073
17 (25.4)

50 (74.6)

0.064

1/week

22 (34.9)

41 (65.1)

26 (41.3)

15 (23.8)

> 1/week

13 (50.0)

13 (50.0)

6 (23.1)

7 (26.9)

No

36 (30.5)

82 (69.5)

42 (35.6)

40 (33.9)

Yes

16 (42.1)

22 (57.9)

12 (31.6)

10 (26.3)

52 (33.3)

104 (66.7)

54 (34.6)

50 (32.1)

Alcohol consumption

0.219

0.235*

0.405*

Smoking status
No

Unless otherwise indicated, Chi squared test was used to assess significance of association between the baseline characteristics and fertility status
* Fisher exact test for test of association
‡

Significance of difference comparing Ovulatory control and PCOS group using Independent t-test

†

Significance of difference comparing Ovulatory control, Non-obese PCOS, and Obese PCOS group using One-way ANOVA

–
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Fig. 1 Variability of adipokines and their ratios between ovulatory and aPCOS groups. a, c Density plots showing distribution of adipokines. b
Comparison of adipokines and their ratios between case and control groups. Mann–Whitney U test was used to assess significance of difference of
adipokines and their ratios between ovulatory and aPCOS groups. d Comparison of adipokines and their ratios. Kruskal–Wallis H test was used to
assess significance of difference of adipokines and their ratios between ovulatory (OC), non-obese (NOP), and obese PCOS (OP) groups. Post-hoc
multiple comparisons was by Dunn’s test. ns not significant, *significant at p < 0.05, ***significant at p < 0.0001

Among the aPCOS group, adiponectin showed a significant negative correlation with BMI (rs = − 0.43,
p < 0.0001), WHtR (rs = − 0.36, p < 0.0001), BAI
(rs = − 0.35, p < 0.0001), and VAI (rs = − 0.19, p = 0.049).
Leptin had a positive correlation with BMI (rs = 0.31,
p = 0.001), WHtR (rs = 0.27, p = 0.007), and BAI
(rs = 0.29, p = 0.003). There was no statistically significant correlation between resistin and obesity indices.
A:L showed a negative correlation with BMI (rs = − 0.48,
p < 0.0001), WHtR (rs = − 0.38, p < 0.0001), and BAI
(rs = − 0.40, p < 0.0001). A:R showed similar correlations while L:R showed a positive correlation with BMI
(rs = 0.27, p = 0.005) and BAI (rs = 0.29, p = 0.003)
(Fig. 2a and Additional file 1: Table S1). Among the controls, adiponectin showed a significantly negative correlation with BAI (rs = − 0.33, p = 0.017) while resistin
showed a positive correlation with WHR (rs = 0.31,
p = 0.028) and WHtR (rs = 0.28, p = 0.044). There was
no statistically significant correlation between leptin and

obesity indices. A:L had a significant negative correlation
with BMI (rs = − 0.36, p = 0.008) and BAI (rs = − 0.39,
p = 0.004) while A:R showed a significant negative correlation with BMI (rs = − 0.29, p = 0.038) (Fig. 2b and
Additional file 1: Table S2).
A:L presented with the best discriminatory power in
predicting aPCOS (AUC = 0.83) followed by adiponectin alone (AUC = 0.79), and L:R and leptin alone (both
AUC = 0.69). Resistin alone presented with the poorest
discriminatory power (AUC = 0.48) (Fig. 2c).
Discussion

Evidence suggest that, in PCOS, high body fat coupled
with dysfunction of adipose tissue result in over-production of leptin, resistin and reduced expression of
adiponectin. Levels of adiponectin have been shown to
decrease in obesity and increase with weight loss [29].
It is considered a ‘beneficial’ adipokine in reproduction
[38]. Leptin is constitutively secreted by adipocytes
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Fig. 2 Correlational analysis and the performance of individual adipokines and their ratios in predicting aPCOS. a Correlation among aPCOS group.
b Correlation among ovulatory control group. Hierarchical clustering by Spearman’s correlation was used to assess relationship between adipokines
and their ratios with obesity indices. Blue-red coloration represents min (−) to max (+) correlation coefficient. c Receiver operating characteristic
(ROC) curve was based on binary logistic regression and discriminant classification analysis for aPCOS and control groups. †Test direction is negative
(smaller test results indicate presence of condition). A:L ratio adiponectin:leptin ratio, A:R ratio adiponectin:resistin ratio, L:R ratio leptin:resistin ratio

in proportion to the adipose mass [39]. In obesity,
the levels of leptin are even more elevated due to leptin resistance [40]. Additionally, increased expression
of the resistin gene has been observed in human preadipocytes, which decreased during adipocyte differentiation. Some studies report comparable adiponectin,
leptin and resistin levels in PCOS [19, 24, 28] whiles
others report lower adiponectin [18], higher leptin [22]
and resistin levels [29] among women with PCOS than
controls in relation to obesity. Thus, reports regarding

the levels of adiponectin, leptin, and resistin in PCOS
remain unresolved.
In this study, aPCOS patients had significantly lower
levels of adiponectin, A:L, and A:R but higher leptin
and L:R compared to the controls. Our finding is comparable to a study by Sarray et al. [28], who reported
significantly lower levels of adiponectin, A:L, and A:R
among women with PCOS compared to controls in
Bahrain. A recent study by Baldani et al. also found significantly lower adiponectin and higher leptin among
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women with PCOS compared to controls in Croatia
[41]. Upon stratification of aPCOS group by obesity
status, we found the obese aPCOS group to have a significantly lower adiponectin, A:L, and A:R but higher
leptin and L:R compared to the non-obese aPCOS and
ovulatory group, respectively. This finding is in harmony with a study by Olszanecka-Glinianowicz et al.
[17] who found serum adiponectin and A:R to be lowest in the obese PCOS subgroup compared to both
the normal weight PCOS subgroup and the controls
in Poland. In their study, serum resistin levels did not
differ significantly between both non-obese and obese
PCOS subgroups and the controls which is comparable to our study findings. Studies by Xiu et al. [42],
Arikan et al. [43], and Seow et al. [44] also found similar serum resistin levels among controls, non-obese,
obese women with PCOS. Furthermore, Sarray et al.
[28] found markedly reduced A:L and A:R among obese
women with PCOS compared to non-obese women
with PCOS and controls. They also found lower L:R
among obese women with PCOS though not statistically significant. Together with previous findings, our
results corroborate the deposition that high body fat
indeed paly pivotal roles in the pathogenesis of PCOS.
Also consistent with previous reports [39, 40, 45–47],
we found that, with the exception of resistin, all other
adipokines including their ratios were strongly and more
correlated with various obesity indices among women
with aPCOS compared to the controls. Specifically, adiponectin, A:L, and A:R showed a negative associations
whereas leptin, and L:R correlated positively with the
obesity indices. This finding is also coherent with studies
by Sarray et al. [28] and Golbahar et al. [48].
In order to assess the predictive capabilities of the adipokines and their ratios, we employed the ROC curve
analysis with reference to aPCOS. We found A:L to have
the best discriminatory power in predicting aPCOS
with an AUC of 0.83, followed by adiponectin alone
(AUC = 0.79). Adiponectin and leptin are adipose tissuederived hormones with contrasting relationship with
the metabolic dysregulation [48]. Previous studies have
highlighted A:L as a biomarker for obesity IR, and stroke
[30–33]. Given the high AUC, our finding suggest that
A:L could be a useful marker for aPCOS. This finding
corroborates with a study by Golbahar et al. who found
A:L to have a similarly high discriminatory power with
comparable AUC of 0.86 among Bahraini women with
PCOS [48]. Sarray et al. found a much higher discriminatory power (AUC of 0.94) for A:L in predicting PCOS
in Bahrain [28]. The discrepancy in the predictive power
may be attributed to differences in characteristics of the
study population, sample size, and methods for biochemical analysis.
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Conclusion

This study shows significantly altered serum adiponectin and leptin levels but not resistin in Ghanaian women with aPCOS compared to healthy subjects.
Obese aPCOS patients have the most altered levels of
adipokines compared to non-obese aPCOS and healthy
subjects. Adiponectin: leptin ratio is the best predictor
of aPCOS compared to individual adipokines.

Limitations
We did not assess androgens levels of the participants.
Also, levels of insulin or IR was not evaluated. Furthermore, the relatively small sample size is a limitation of
this present study. We recommend the use of larger
sample size in future studies.

Additional file
Additional file 1. Correlation co-efficient, lipid profile and anthropomet‑
ric characteristics of the study population.
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